Cosmo announces its licensee Dr. Falk Pharma received approval in the European Decentralized Procedure for Relafalk (Rifamycin SV MMX) in Travelers’ Diarrhea
Cosmo Pharmaceuticals N.V. announces that its licensee Dr. Falk Pharma has received today approval in the European Decentralized Procedure (DCP) for Relafalk (Rifamycin SV MMX) for the treatment of Travelers’ Diarrhea. This approval follows the approval of AEMCOLO (Rifamycin SV MMX) by the FDA on November 16 for the same indication.
The DCP concerned the following Member States: Germany, United Kingdom, Spain, Denmark, Greece, Finland, Hungary, Norway, Portugal, Poland, Sweden and Bulgaria.